Matthew Galsky
- ASSOCIATE PROFESSOR Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR Urology
Print Profile
Specialty
Certifications
Medical Oncology
Clinical Focus
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Tumors
- Urologic Cancers
Education
MD, Tufts University School of Medicine
Residency, Internal Medicine
Beth Israel Deaconess Medical Center- Harvard Medical SchoolFellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
Biography
- Dr. Galsky specializes in the care of patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the development of novel treatments for these cancers and he has published extensively in this area. He serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute.
Awards
2003 -
American Society of Clinical Oncology Merit Award
1998 -
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
1998 -
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
1997 -
Alpha Omega Alpha Honor Society
Clinical Trials
- Phase IB study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors
- Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
- Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 (Kidney)
- Multi-center Phase 2 Trial of Single-agent Amrubicin as second-line therapy in patients with Advanced/Metastatic Refractory Urothelial Carcinoma
- Multi-Center Phase IB/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-Line Therapy for Patients with Metastatic Urothelial Carcinoma
- A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Galsky during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- BioMotiv, LLC
Scientific Advisory Board:
- Astellas Pharma Inc.; Dendreon Corporation; GlaxoSmithKline; Janssen Biotech, Inc., formerly Centocor Biotech, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave Levy Place
Box 1079
New York, NY 10029
1470 Madison Avenue
3rd floor
New York, NY 10029
